The Journal of Critical Psychology, Counselling and Psychotherapy (JCPCP)

Contents (Special Edition: Withdrawal from Prescribed Psychotropic Drugs)

Edited by Peter Lehmann

• Dr. Caligari reflects back and looks forward
  David L. Richman




• The patient voice: Antidepressant withdrawal, medically unexplained symptoms and functional neurological disorders
  Marion Brown and Stevie Lewis




• Highlighting individuality requires tailored prescribing during recovery
  Jann E. Schlimme and Michael A. Schwartz




• Minimum dosage and monitoring of neuroleptics
  Volkmar Aderhold




• The Observatory for Mental Health Rights: Cooperative support in withdrawal
  Anna Emmanouelidou




• Attitudes of researchers about discontinuation of psychopharmacological treatment
  Fernando Freitas, Fabio Mota, Luiza Amara Maciel Braga and Camila Motta




• Discontinuing psychotropic drugs? And if so, how?
  Volkmar Aderhold, Peter Lehmann, Marc Rufer and Josef Zehentbauer




• Using the Wellness Recovery Action Plan to withdraw from psychiatric medications
  Mary Ellen Copeland




• Do antipsychotics reduce the risk of relapse?
  Robert Whitaker




• The prospect of recovering compensation for psychiatric withdrawal harm through litigation because of missing or misleading information
  James B. Gottstein




• And finally atypically careful
  Susanne Cortez